.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BX04_Relugolix.Relugolix .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BX04_Relugolix.Relugolix| name: | Relugolix |
| ATC code: | L02BX04 | route: | oral |
| n-compartments | 2 |
Relugolix is a non-peptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced prostate cancer and uterine fibroids. It works by reducing the amounts of luteinizing hormone and follicle-stimulating hormone, thereby lowering testosterone or estrogen levels. It is approved for clinical use.
Population pharmacokinetic parameters in adult males with advanced prostate cancer after multiple oral doses. Parameters are based on data from healthy adult volunteers and prostate cancer patients.
George, DJ, et al., & Shore, ND (2023). Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical genitourinary cancer 21(3) 383–392.e2. DOI:10.1016/j.clgc.2023.03.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37062659
Suzuki, H, et al., & Suzuki, K (2019). Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. Cancer medicine 8(13) 5891–5902. DOI:10.1002/cam4.2442 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31429205